Zacks: Analysts Anticipate BioScrip Inc (BIOS) Will Post Quarterly Sales of $177.51 Million

Equities research analysts forecast that BioScrip Inc (NASDAQ:BIOS) will announce sales of $177.51 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for BioScrip’s earnings, with the highest sales estimate coming in at $178.00 million and the lowest estimate coming in at $177.01 million. BioScrip posted sales of $168.58 million in the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The company is expected to announce its next earnings report on Thursday, May 9th.

On average, analysts expect that BioScrip will report full-year sales of $754.46 million for the current fiscal year, with estimates ranging from $750.72 million to $761.65 million. For the next year, analysts expect that the business will report sales of $800.52 million, with estimates ranging from $794.00 million to $807.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow BioScrip.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Friday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.11). The business had revenue of $183.57 million during the quarter, compared to analyst estimates of $188.39 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. The firm’s quarterly revenue was up .5% on a year-over-year basis.

A number of equities analysts have issued reports on BIOS shares. BidaskClub cut BioScrip from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 27th. Zacks Investment Research cut BioScrip from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Stephens cut BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 target price for the company. in a report on Monday, March 18th. Canaccord Genuity lowered their target price on BioScrip from $5.00 to $3.50 and set a “buy” rating for the company in a report on Monday, March 18th. Finally, TheStreet cut BioScrip from a “c-” rating to a “d” rating in a report on Wednesday, April 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $4.70.

BIOS traded down $0.01 on Friday, reaching $1.76. The stock had a trading volume of 39,119 shares, compared to its average volume of 2,054,197. BioScrip has a fifty-two week low of $1.69 and a fifty-two week high of $4.14. The stock has a market cap of $225.54 million, a PE ratio of -3.58 and a beta of 0.69.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caxton Associates LP acquired a new position in BioScrip during the 4th quarter worth approximately $52,000. Vanguard Group Inc. increased its position in shares of BioScrip by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after acquiring an additional 27,904 shares during the last quarter. Tibra Equities Europe Ltd purchased a new stake in shares of BioScrip during the fourth quarter valued at approximately $503,000. Menta Capital LLC purchased a new stake in shares of BioScrip during the fourth quarter valued at approximately $124,000. Finally, BlackRock Inc. increased its position in shares of BioScrip by 0.4% during the third quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock valued at $23,610,000 after acquiring an additional 31,899 shares during the last quarter. Hedge funds and other institutional investors own 82.40% of the company’s stock.

BioScrip Company Profile

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Featured Article: What is the balance sheet?

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.